Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenFRA:IDP +0.42%68 EV-to-EBITDA is 17.49 as of Aug. 02, 2026, which is 73% above its 10-year median of 10.09. GuruFocus rates FRA:IDP with a GF Score™ of 68/100 and a GF Value™ of €170.97 (Fairly Valued). The stock has 9 warning signs investors should review. Among 746 Drug Manufacturers companies, Biogen ranks worse than 62.87% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biogen's enterprise value is €32,159 Mil.
Biogen's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1,839 Mil. Therefore, Biogen's EV-to-EBITDA for today is 17.49.
The historical rank and industry rank for Biogen's EV-to-EBITDA or its related term are showing as below:
FRA:IDP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.43 Med: 10.09 Max: 21.54
Current: 17.32
During the past 13 years, the highest EV-to-EBITDA of Biogen was 21.54. The lowest was 5.43. And the median was 10.09.
FRA:IDP's EV-to-EBITDA is ranked worse than 62.87% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs FRA:IDP: 17.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-02), Biogen's stock price is €178.92.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €4.852. Therefore, Biogen's PE Ratio (TTM) for today is 36.88.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biogen's share price for today is €178.92.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.852.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biogen's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IDP vs OGN, AMRN, SCLX: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Biogen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biogen's EV-to-EBITDA falls into.
Biogen's current Enterprise Value is €32,159 Mil.
Biogen's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,839 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (FRA:IDP) has a EV-to-EBITDA of 17.49 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biogen. This is 73% above median its historical median of 10.09. Over the past decade, Biogen's EV-to-EBITDA has ranged from 5.43 to 21.54. According to the industry distribution chart, Biogen ranks #469 out of 746 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is Biogen's EV-to-EBITDA too high?
Biogen's current EV-to-EBITDA of 17.49 is 73% above median its 10-year median of 10.09. Over the past 10 years, this metric has ranged from a low of 5.43 to a high of 21.54. The Drug Manufacturers industry median EV-to-EBITDA is 13.00. Biogen's value of 17.49 is 34.6% above this industry median. Based on the distribution chart, Biogen ranks #469 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biogen has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's EV-to-EBITDA compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #469 out of 746 companies for EV-to-EBITDA. This places Biogen in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. Biogen's value of 17.49 is 34.6% above this benchmark. Historically, Biogen's own EV-to-EBITDA has ranged from 5.43 to 21.54 over the past decade. While the company's 10-year median is 10.09 vs. the industry median of 13.00, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current EV-to-EBITDA of 17.49 is 34.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biogen. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current EV-to-EBITDA is 17.49, which is 73% above median its own 10-year median of 10.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (FRA:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €170.97, compared to a current price of €178.92 — trading 4.6% above its estimated fair value. The current EV-to-EBITDA is 17.49, which is 73% above median its 10-year median of 10.09 and 34.6% above the Drug Manufacturers industry median of 13.00. Biogen's overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biogen (FRA:IDP), the current EV-to-EBITDA is 17.49 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (FRA:IDP) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of €178.92 is trading 4.6% above its estimated GF Value™ of €170.97.
GuruFocus considers Biogen to be Fairly Valued.
Key valuation signals for FRA:IDP:
EV-to-EBITDA: 17.49 (73% above median its 10-year median of 10.09)
GF Value™: €170.97 vs. price of €178.92 (4.6% above fair value)
Industry Position: 34.6% above the Drug Manufacturers median (#469 of 746)
No single metric tells the full story. See the FRA:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
68GF Score
Get the complete analysis for FRA:IDP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IDP has been successfully added to your 
